Efficacy and safety endpoints of Ranolazine in comparison with conventional therapy in reduction of HbA1c percentage in type 2 diabetic patients with ischemic heart disease

Samin Daroo Company0 个研究点目标入组 60 人开始时间: 待定最近更新: 2019年1月14日

适应症

试验速览

暂无简介。

•HbA1c more than 6.5%, Age more than 50 year, both genders with diabetes mellitus and coronary artery disease (CAD)
•Experiencing chronic stable angina for at least 3 months triggered by physical effort and relieved by rest and/or sublingual nitroglycerin
•CAD documented by one or more of the following: Angiography evidence of more than 50% stenosis of one or more coronary arteries, History of MI, cardiac imaging or exercise test diagnostic for CAD
•Treatment with up to 2 anti-anginal therapies at a stable dose for at least 2 weeks before starting the trial
•T2DM patients who use Metformin and Gliclazide

•New York Heart Association class III and IV
•Acute coronary syndrome in the prior 2 months or planned for coronary revascularization
•Stroke or transient ischemic attack within 6 months prior
•QTc more than 500 ms
•Systolic blood pressure more than 180, diastolic blood pressure more than 110 mmHg
•Liver cirrhosis
•Prior treatment with CYP 3A4 inhibitors or P GlyP inductors
•Treatment with anti arrhythmic medicine class ll and lll
•Alcohol consumption or drug users
•Simvastatin consumption

发起方

Samin Daroo Company